These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2163811)

  • 1. The effect of partial noncompliance on the power of a clinical trial.
    Freedman LS
    Control Clin Trials; 1990 Jun; 11(3):157-68. PubMed ID: 2163811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Planning the analysis of a breast cancer prevention trial.
    Moon TE
    Prev Med; 1991 Jan; 20(1):109-18. PubMed ID: 2008420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statistical design of the Women's Health Trial.
    Self S; Prentice R; Iverson D; Henderson M; Thompson D; Byar D; Insull W; Gorbach SL; Clifford C; Goldman S
    Control Clin Trials; 1988 Jun; 9(2):119-36. PubMed ID: 3396363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of treatment noncompliance on power in a 2 x 2 factorial design.
    Lindblad AS
    J Biopharm Stat; 1996 Jul; 6(3):263-70. PubMed ID: 8854231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Causal inference methods to assess safety upper bounds in randomized trials with noncompliance.
    Wang Y; Berlin JA; Pinheiro J; Wilcox MA
    Clin Trials; 2015 Jun; 12(3):265-75. PubMed ID: 25733675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dichotomizing partial compliance and increased participant burden in factorial designs: the performance of four noncompliance methods.
    Merrill PD; McClure LA
    Trials; 2015 Nov; 16():523. PubMed ID: 26573840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspects of the science of cancer prevention trials: lessons from the conduct and planning of clinical trials of a low-fat diet intervention among women.
    Prentice RL
    Prev Med; 1991 Jan; 20(1):147-57. PubMed ID: 2008423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Planning the size of clinical trials with allowance for patient noncompliance.
    Moussa MA
    Methods Inf Med; 1990 Jul; 29(3):243-6. PubMed ID: 2215266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bounds on the average causal effects in randomized trials with noncompliance by covariate adjustment.
    Shan N; Xu PF
    Biom J; 2016 Nov; 58(6):1311-1318. PubMed ID: 27062639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Test non-inferiority and sample size determination based on the odds ratio under a cluster randomized trial with noncompliance.
    Lui KJ; Chang KC
    J Biopharm Stat; 2011 Jan; 21(1):94-110. PubMed ID: 21191857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noncompliance in cancer screening trials.
    Gareen IF
    Clin Trials; 2007; 4(4):341-9. PubMed ID: 17848495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Test homogeneity of odds ratio in a randomized clinical trial with noncompliance.
    Lui KJ; Chang KC
    J Biopharm Stat; 2009 Sep; 19(5):916-32. PubMed ID: 20183452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Likelihood methods for treatment noncompliance and subsequent nonresponse in randomized trials.
    O'Malley AJ; Normand SL
    Biometrics; 2005 Jun; 61(2):325-34. PubMed ID: 16011678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simple efficient bias corrected instrumental variable estimator for randomized trials with noncompliance.
    Chan KC
    Contemp Clin Trials; 2012 Jul; 33(4):786-93. PubMed ID: 22484340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design issues for a breast cancer chemoprevention trial.
    DeMets DL; Newcomb PA; Carey P
    Prev Med; 1991 Jan; 20(1):101-8. PubMed ID: 2008419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sample size determination for testing equality in a cluster randomized trial with noncompliance.
    Lui KJ; Chang KC
    J Biopharm Stat; 2011 Jan; 21(1):1-17. PubMed ID: 21191850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment noncompliance in randomized experiments: statistical approaches and design issues.
    Sagarin BJ; West SG; Ratnikov A; Homan WK; Ritchie TD; Hansen EJ
    Psychol Methods; 2014 Sep; 19(3):317-33. PubMed ID: 24773358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sample size determination in clinical trials with time-dependent rates of losses and noncompliance.
    Lakatos E
    Control Clin Trials; 1986 Sep; 7(3):189-99. PubMed ID: 3802834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bayesian hierarchical model estimating CACE in meta-analysis of randomized clinical trials with noncompliance.
    Zhou J; Hodges JS; Suri MFK; Chu H
    Biometrics; 2019 Sep; 75(3):978-987. PubMed ID: 30690716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of a randomized trial of a low-fat diet for the prevention of breast cancer: dietary compliance in the Women's Health Trial Vanguard Study.
    Henderson MM; Kushi LH; Thompson DJ; Gorbach SL; Clifford CK; Insull W; Moskowitz M; Thompson RS
    Prev Med; 1990 Mar; 19(2):115-33. PubMed ID: 2193306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.